Events and Presentations Events and Presentations Upcoming Events There are no upcoming events available at this time. Past Events November 16, 2020 at 3:20 PM EST Stifel Virtual Healthcare Conference Click here to register November 9, 2020 at 10:15 AM EST Credit Suisse Virtual Healthcare Conference Click here to register September 15, 2020 at 9:20 AM EDT Cantor Virtual Global Healthcare Conference Click here for webcast August 12, 2020 at 2:30 PM EDT Stoke Therapeutics at Canaccord Genuity 40th Annual Growth Conference Click here for webcast August 11, 2020 at 2:00 PM EDT Stoke Therapeutics at BTIG Virtual Biotechnology Conference Click here for webcast August 11, 2020 at 11:30 AM EDT Stoke Therapeutics at 2020 Wedbush PacGrow Healthcare Virtual Conference Click here for webcast June 12, 2020 Stoke Therapeutics at Association for Research in Vision & Ophthalmology Meeting 2020 Supporting Materials Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy 3.7 MB Corporate Presentation Corporate Presentation – November 2020 Key Publications August 26, 2020 Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome Source Science Translational Medicine July 9, 2020 Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression Source Nature Communications Genetic Epilepsies Presentations December 8, 2019 TANGO oligonucleotides for the treatment of Dravet Syndrome: Safety, biodistribution and pharmacology in the non-human primate Source AES 2019 December 7, 2019 Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a Prevents SUDEP in a mouse model of Dravet Syndrome Source AES 2019 December 1, 2018 TANGO – Targeted Augmentation of Nuclear Gene Output for the Treatment of Dravet Syndrome Source American Epilepsy Society Annual Meeting May 11, 2018 TANGO – Targeted Augmentation of Nuclear Gene Output for the Treatment of Genetic Diseases Source American Society of Gene and Cell Therapy Annual Meeting Ophthalmology Presentations June 12, 2020 Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy Source ARVO 2020 May 12, 2020 POSTER: Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy Source ASGCT 2020 Toolkit Print Page Email Alerts Contact IR FAQ
Events and Presentations Upcoming Events There are no upcoming events available at this time. Past Events November 16, 2020 at 3:20 PM EST Stifel Virtual Healthcare Conference Click here to register November 9, 2020 at 10:15 AM EST Credit Suisse Virtual Healthcare Conference Click here to register September 15, 2020 at 9:20 AM EDT Cantor Virtual Global Healthcare Conference Click here for webcast August 12, 2020 at 2:30 PM EDT Stoke Therapeutics at Canaccord Genuity 40th Annual Growth Conference Click here for webcast August 11, 2020 at 2:00 PM EDT Stoke Therapeutics at BTIG Virtual Biotechnology Conference Click here for webcast August 11, 2020 at 11:30 AM EDT Stoke Therapeutics at 2020 Wedbush PacGrow Healthcare Virtual Conference Click here for webcast June 12, 2020 Stoke Therapeutics at Association for Research in Vision & Ophthalmology Meeting 2020 Supporting Materials Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy 3.7 MB Corporate Presentation Corporate Presentation – November 2020 Key Publications August 26, 2020 Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome Source Science Translational Medicine July 9, 2020 Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression Source Nature Communications Genetic Epilepsies Presentations December 8, 2019 TANGO oligonucleotides for the treatment of Dravet Syndrome: Safety, biodistribution and pharmacology in the non-human primate Source AES 2019 December 7, 2019 Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a Prevents SUDEP in a mouse model of Dravet Syndrome Source AES 2019 December 1, 2018 TANGO – Targeted Augmentation of Nuclear Gene Output for the Treatment of Dravet Syndrome Source American Epilepsy Society Annual Meeting May 11, 2018 TANGO – Targeted Augmentation of Nuclear Gene Output for the Treatment of Genetic Diseases Source American Society of Gene and Cell Therapy Annual Meeting Ophthalmology Presentations June 12, 2020 Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy Source ARVO 2020 May 12, 2020 POSTER: Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy Source ASGCT 2020
August 12, 2020 at 2:30 PM EDT Stoke Therapeutics at Canaccord Genuity 40th Annual Growth Conference Click here for webcast
August 11, 2020 at 2:00 PM EDT Stoke Therapeutics at BTIG Virtual Biotechnology Conference Click here for webcast
August 11, 2020 at 11:30 AM EDT Stoke Therapeutics at 2020 Wedbush PacGrow Healthcare Virtual Conference Click here for webcast
June 12, 2020 Stoke Therapeutics at Association for Research in Vision & Ophthalmology Meeting 2020 Supporting Materials Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy 3.7 MB
Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy 3.7 MB
August 26, 2020 Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome Source Science Translational Medicine
July 9, 2020 Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression Source Nature Communications
December 8, 2019 TANGO oligonucleotides for the treatment of Dravet Syndrome: Safety, biodistribution and pharmacology in the non-human primate Source AES 2019
December 7, 2019 Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a Prevents SUDEP in a mouse model of Dravet Syndrome Source AES 2019
December 1, 2018 TANGO – Targeted Augmentation of Nuclear Gene Output for the Treatment of Dravet Syndrome Source American Epilepsy Society Annual Meeting
May 11, 2018 TANGO – Targeted Augmentation of Nuclear Gene Output for the Treatment of Genetic Diseases Source American Society of Gene and Cell Therapy Annual Meeting
June 12, 2020 Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy Source ARVO 2020
May 12, 2020 POSTER: Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy Source ASGCT 2020